相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia
Paul La Rosee et al.
CURRENT OPINION IN HEMATOLOGY (2010)
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Theo D. Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment
C. Haferlach et al.
LEUKEMIA (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
Margret S. Fernandes et al.
BLOOD (2009)
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway
R. Naughton et al.
LEUKEMIA (2009)
BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations
Tomasz Stoklosa et al.
CANCER RESEARCH (2008)
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair
Kimberly Cramer et al.
CANCER RESEARCH (2008)
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Heiko Konig et al.
CANCER RESEARCH (2008)
Cryptic and Partial Deletions of PRDM16 and RUNX1 Without t(1;21)(p36;q22) and/or RUNX1-PRDM16 Fusion in a Case of Progressive Chronic Myeloid Leukemia: A Complex Chromosomal Rearrangement of Underestimated Frequency in Disease Progression?
Laureline Deluche et al.
GENES CHROMOSOMES & CANCER (2008)
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
Jamshid S. Khorashad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress
M. Koptyra et al.
LEUKEMIA (2008)
Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis
J. S. Khorashad et al.
LEUKEMIA (2008)
BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts
Tomasz Skorski
LEUKEMIA & LYMPHOMA (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression
D. Brazma et al.
GENES CHROMOSOMES & CANCER (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
Alice Fabarius et al.
HAEMATOLOGICA (2007)
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
Xiaoyan Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Heather G. Jorgensen et al.
BLOOD (2007)
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment
Cornelius Miething et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Fusion tyrosine kinases: a result and cause of genomic instability
E. T. P. Penserga et al.
ONCOGENE (2007)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Mateusz Koptyra et al.
BLOOD (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
Hans-Guido Wendel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
RT Williams et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells
A Slupianek et al.
DNA REPAIR (2006)
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate
HG Jorgensen et al.
CLINICAL CANCER RESEARCH (2006)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
SG Willis et al.
BLOOD (2005)
Induction of centrosome and chromosome aberrations by imatinib in vitro
A Fabarius et al.
LEUKEMIA (2005)
Chronic myeloid leukaemia: stem cell derived but progenitor cell driven
SB Marley et al.
CLINICAL SCIENCE (2005)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli
MS Holtz et al.
LEUKEMIA (2005)
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center -: A 4.5-year follow-up
T Lahaye et al.
CANCER (2005)
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment
S Chu et al.
BLOOD (2005)
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression
U Bacher et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
MO Nowicki et al.
BLOOD (2004)
Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia
N Sorel et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Clonal evolution in chronic myelogenous leukemia
J Cortes et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
The interacting pathways for prevention and repair of oxidative DNA damage
G Slupphaug et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2003)
BCR-ABL-induced adhesion defects are tyrosine kinase-independent
JA Wertheim et al.
BLOOD (2002)
Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis
A Slupianek et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis
C Bernstein et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2002)
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
MS Holtz et al.
BLOOD (2002)
Activation of human MutS homologs by 8-oxo-guanine DNA damage
A Mazurek et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia
B Johansson et al.
ACTA HAEMATOLOGICA (2002)
Visualization of recombination intermediates produced by RAD52-mediated single-strand annealing
E Van Dyck et al.
EMBO REPORTS (2001)
BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance
A Slupianek et al.
MOLECULAR CELL (2001)
The contribution of endogenous sources of DNA damage to the multiple mutations in cancer
AL Jackson et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Genomic instability: potential contributions to tumour and normal tissue response, and second tumours, after radiotherapy
JH Hendry
RADIOTHERAPY AND ONCOLOGY (2001)
Spontaneous DNA damage, genome instability, and cancer -: When DNA replication escapes control
P Schär
CELL (2001)
Repair of oxidative DNA damage - Mechanisms and functions
AL Lu et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2001)
Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells
C Richardson et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells
M Sattler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
